Insulin Resistance and Testosterone in Women

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

35 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-07-31

Study Completion Date

2011-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this research study is to determine if a relationship between insulin resistance (IR) and testosterone (T) exists in women who have already gone through menopause.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of Varying Testosterone Levels on Insulin Sensitivity in Normal and IHH Men

NCT00470990

Hypogonadism

COMPLETED NA

Insulin Sensitivity in Men With the Metabolic Syndrome

NCT00433173

Metabolic Syndrome

SUSPENDED NA

Testosterone Replacement in Men With Diabetes and Obesity

NCT01127659

Hypogonadism

COMPLETED PHASE4

TDSM- Testosterone Dose Response in Surgically Menopausal Women

NCT00494208

Hysterectomy Ovariectomy Menopause +1 more

COMPLETED NA

T-IR- Study to Understand the Effects of Testosterone and Estrogen on the Body's Response to the Hormone Insulin

NCT01686828

Insulin Resistance Type 2 Diabetes Mellitus Obesity +2 more

COMPLETED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study tests the central hypothesis that insulin resistance (IR) increases androgen (male sex hormone) production in postmenopausal women. Participation will include five visits, each lasting on average 2.5 hours, over a period of 13-20 weeks.

At the screening visit, the participant's medical history, current use of medications and dietary supplements, and social habits will be recorded. This information will be reviewed on each subsequent visit; participants are asked to maintain their current diet and physical activity level throughout the study.

A brief physical exam will be performed, and blood will be drawn.

At the 2nd (baseline) visit, patients will undergo a euglycemic-hyperinsulinemic clamp (a procedure to measure insulin sensitivity by continuous intravenous infusion of insulin, and variable infusion of glucose). Blood samples will be drawn throughout the procedure. At completion, the insulin infusion will be stopped, participants will be fed, and the glucose infusion continued for at least 15 minutes to ensure stability of the blood glucose concentration. After the procedure, participants will be randomized to receive either metformin plus leuprolide placebo, leuprolide plus metformin placebo, or metformin placebo plus leuprolide placebo. The leuprolide or leuprolide placebo will be administered as an injection by a nurse. The metformin or metformin placebo will be dispensed to the participant in the form of pills, with instructions for titrating the dose. Participants will be contacted by telephone once weekly during the titration period to assess drug tolerability and adverse events (AEs). Participants will be maintained at their maximum tolerated dose for the duration of the study intervention period.

Participants will return every 4 weeks for follow-up. Blood will be drawn, the nurse will administer the leuprolide or leuprolide placebo injection, and metformin or metformin placebo will be dispensed. At the final visit (week 12), participants will undergo a brief physical exam, and will then undergo a final euglycemic-hyperinsulinemic clamp.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Insulin Resistance Postmenopause

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

metformin pill plus placebo injection

Group Type EXPERIMENTAL

metformin

Intervention Type DRUG

Initiated on 500 mg daily and titrated up to 1000 mg twice a day during the first four weeks, remaining at that dose until 12 weeks

placebo injection

Intervention Type DRUG

matching injection every 4 weeks (e.g. baseline, 4, and 8 weeks)

2

leuprolide injection plus placebo pill

Group Type EXPERIMENTAL

leuprolide injection

Intervention Type DRUG

3.75 mg injection every 4 weeks (e.g. at baseline, 4, and 8 weeks)

placebo pill

Intervention Type DRUG

matching pill twice a day for 12 weeks

3

placebo pill plus placebo injection

Group Type PLACEBO_COMPARATOR

placebo pill

Intervention Type DRUG

matching pill twice a day for 12 weeks

placebo injection

Intervention Type DRUG

matching injection every 4 weeks (e.g. baseline, 4, and 8 weeks)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

metformin

Initiated on 500 mg daily and titrated up to 1000 mg twice a day during the first four weeks, remaining at that dose until 12 weeks

Intervention Type DRUG

leuprolide injection

3.75 mg injection every 4 weeks (e.g. at baseline, 4, and 8 weeks)

Intervention Type DRUG

placebo pill

matching pill twice a day for 12 weeks

Intervention Type DRUG

placebo injection

matching injection every 4 weeks (e.g. baseline, 4, and 8 weeks)

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Glucophage Lupron

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Postmenopausal women aged 50-79 years with absence of menses for 12 months; for women 50-54 years, Follicle stimulating hormone\>30 U/mL to confirm postmenopausal status
* At least one intact ovary
* Free testosterone and fasting insulin levels within required study parameters
* Willing to comply with all study-related procedures
* Capable of giving informed consent

Exclusion Criteria

* History of cancer requiring treatment within the past 5 years (exceptions may be made by investigator)
* Hospitalization for treatment of vascular disease in the past 6 months
* Uncontrolled hypertension
* Hospitalization for chronic obstructive pulmonary disease or asthma in the past 3 months
* Use of continuous oxygen at home
* Surgery in the last 30 days
* Positive for HIV
* Abnormal blood tests (hemoglobin, fasting triglycerides, fasting glucose, creatinine, liver function)
* History of diabetes mellitus or use of any anti-hyperglycemic medication in the past 3 months
* Disease associated with disordered glucose metabolism (Cushing's disease, acromegaly, pheochromocytoma not surgically cured, chronic pancreatitis)
* History of chronic renal insufficiency
* Intravenous (IV) contrast studies with iodinated materials planned for the 12 week intervention period that cannot be postponed according to the participant's primary care provider
* Acute or chronic metabolic acidosis
* History of liver disease
* Congestive heart failure
* History of androgen-secreting tumors
* Hormone replacement therapy or antiandrogen use in past 6 months
* Use of dehydroepiandosterone (DHEA) or other androgen-containing products in past 6 months
* Corticosteroid use, other than topical, ophthalmic, intraarticular, and inhaled preparations, in past 3 months
* Undiagnosed current vaginal bleeding
* Excessive alcohol intake, either acute or chronic; current illicit substance abuse
* Participation in an investigational drug study within 6 weeks prior to screening visit
* Serious or unstable medical or psychological conditions that, in the opinion of the investigator, would compromise the patient's safety or successful participation in the study

Minimum Eligible Age

50 Years

Maximum Eligible Age

79 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes